Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 5/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TLR4 | O00206 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95949 | 0.84 | MAOB (0.50) | MAOBAPPNR4A2MAOABCHE | |
| SCHEMBL1283497 | 0.83 | GPR84 (0.52) | MAOBMAOAMEN1KMT2A | |
| SCHEMBL920275 | 0.83 | MAOB (0.54) | MAOBAPPMAOAMAPK1SMN1; SMN2 | |
| SCHEMBL7971499 | 0.83 | MAOB (0.57) | MAOBAPPMAOASMPD1 | |
| SCHEMBL920100 | 0.83 | MAOB (0.53) | MAOBAPPNR4A2MAOA | |
| SCHEMBL8371568 | 0.82 | NPC1 (0.48) | MAOBMAOA | |
| SCHEMBL919538 | 0.82 | MAOB (0.56) | MAOBNR4A2MAOA | |
| SCHEMBL28914634 | 0.82 | MAOB (0.47) | MAOBNR4A2MAOA | |
| SCHEMBL921127 | 0.81 | APP (0.53) | MAOBAPPSMPD1SMN1; SMN2 | |
| SCHEMBL920026 | 0.80 | MAOB (0.60) | MAOBAPPMAOASMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009134754-A1 | BENZOIMIDAZOLE GLYCINAMIDES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | claimed |
| WO-2023085225-A1 | METHOD FOR MANUFACTURING RECYCLED RESIN COMPOSITION | 住友化学株式会社 | 2023-05-19 | — | — | WO | disclosed |
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-04 | — | — | US | disclosed |
| US-20210078978-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-18 | — | — | US | disclosed |
| US-10851083-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-01 | — | — | US | disclosed |
| WO-2020209118-A1 | REVERSIBLY THERMOCHROMIC AQUEOUS INK COMPOSITION FOR WRITING UTENSILS, AND REFILL AND WATER-BASED BALLPOINT PEN EACH INTERNALLY CONTAINING SAME | 株式会社パイロットコーポレーション | 2020-10-15 | — | — | WO | disclosed |
| US-20180215732-A9 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-02 | — | — | US | disclosed |
| US-20180022733-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-25 | — | — | US | disclosed |
| US-20160168127-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-16 | — | — | US | disclosed |
| CN-105308150-A | Thermochromic color-memorizing composition and thermochromic color-memorizing microcapsule pigment encapsulating same | PILOT INK CO LTD | 2016-02-03 | — | — | CN | disclosed |
| EP-2345328-A1 | COMPOSITION FOR AGRICULTURAL USE | Sumitomo Chemical Company, Limited (JP) | 2011-07-20 | — | — | EP | disclosed |
| CN-102076680-A | Benzimidazoles as Prolyl Hydroxylase Inhibitors | JANSSEN PHARMACEUTICA NV | 2011-05-25 | — | — | CN | disclosed |
| EP-2294066-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2011-03-16 | — | — | EP | disclosed |
| US-20110046132-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-24 | — | — | US | disclosed |
| CN-101965386-A | Reversible thermal discoloration aqueous ink composition, writing instrument using the same, and writing instrument set | PILOT INK CO LTD | 2011-02-02 | — | — | CN | disclosed |
| US-20110009454-A1 | COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2248423-A1 | COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS | Sumitomo Chemical Company, Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009134754-A1 | BENZOIMIDAZOLE GLYCINAMIDES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134750-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | disclosed |
| CN-1122800-A | Pyrimidinyl acrylic acid derivatives | SANDOZ LTD (CH) | 1996-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | P4HA1, PAH, EGLN3 | MAOB 167/4885APP 3335/4885NR4A2 2078/4885 |
| US-20110046132-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | MAOB 183/4885APP 3229/4885NR4A2 2132/4885 |
| US-20110009454-A1 | COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS | WIZ, TST, NAT1 | MAOB 3730/4885APP 4020/4885NR4A2 573/4885 |
| US-20180022733-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | MAOB 167/4885APP 3335/4885NR4A2 2078/4885 |
| US-10851083-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | P4HA1, PAH, EGLN3 | MAOB 167/4885APP 3335/4885NR4A2 2078/4885 |
| US-20180215732-A9 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | MAOB 167/4885APP 3335/4885NR4A2 2078/4885 |
| US-20210078978-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | MAOB 167/4885APP 3335/4885NR4A2 2078/4885 |
| US-20160168127-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | MAOB 167/4885APP 3335/4885NR4A2 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.